Register D. Forensic governance pass. Sources: MEC corporate-governance page, Directors page, March 2025 Briefing for Shareholders, December 2025 Nippon-IBR sponsored research, yfinance live institutional + insider data, May 2012 personnel announcement, MarketScreener, Simply Wall St. Japanese-iss…
Register D. Forensic governance pass. Sources: MEC corporate-governance page, Directors page, March 2025 Briefing for Shareholders, December 2025 Nippon-IBR sponsored research, yfinance live institutional + insider data, May 2012 personnel announcement, MarketScreener, Simply Wall St. Japanese-issuer caveat: deeper NEO-level compensation detail lives in the Yuho (Japanese annual securities report), which is not fully translated.
This is a long-tenured operator with a clear track record of building MEC’s Asia presence. The combination of 24 years as President + ~4% personal stake + R&D-led culture commitment is unusually strong for a Japanese mid-cap.
| Name | Role | Shares | % out | Est. value | How acquired |
|---|---|---|---|---|---|
| Kazuo Maeda | CEO & President | ~727K | 3.98% | ~$49M | Mix — likely accumulated open-market + stock-based comp via treasury grants |
| Sadamitsu Sumitomo | Director, EOO Global Ops | ~20K | 0.11% | ~$1.4M | Likely SBC |
| Mitsutoshi Takao | Outside Director (AC Chair) | ~3K | 0.016% | ~$202K | SBC |
| Kaoru Hashimoto | Outside Director (AC) | ~600 | 0.0033% | ~$40K | SBC |
| Eiji Miyashita | Outside Director (AC) | ~500 | 0.0027% | ~$34K | SBC |
| Tetsuya Taniguchi | Director, EOO | — | n/a | — | n/a |
| Lucinda Lohman-Oota | Outside Director | — | n/a | — | n/a |
| Aggregate “insiders” | — | 3,537,242 | 18.45% | ~$222M | Mix |
The 18.45% aggregate (per yfinance major holders) vs the ~4.1% of named board executives implies that a large block (~14%) is held by other insiders not listed on the directors page — most likely founder family, executive officers below board level, employee shareholding plan, or related strategic holders. The Japanese Yuho 大株主 table (top-10 shareholders) would resolve this. This is the single largest forensic gap in the public English filings.
Japan has an equivalent disclosure regime (TDnet trading rule disclosures) but they’re not consistently disclosed in English. No automatic-sell programmes flagged.
Not visible at this disclosure level. Maeda’s 3.98% stake almost certainly accumulated through a combination of long tenure SBC grants and open-market purchases over 24 years; without the Yuho I can’t decompose. Flagged as a follow-up.
| Name | Role | MEC stake | Other public-co holdings | Private/shell interests | Wealth concentration |
|---|---|---|---|---|---|
| Kazuo Maeda | CEO | $49M / 3.98% | None disclosed | None disclosed | Highly concentrated in MEC (multiple decades, multi-subsidiary Representative Director) |
| Sumitomo, Taniguchi | EOO | <$1.5M each | None disclosed | None disclosed | Likely concentrated in MEC |
| Outside directors | OD | <$250K each | Not mapped | Not mapped | Outside directors’ wealth is presumably elsewhere — these are governance roles, not ownership roles |
Maeda’s wealth profile is the relevant one. A 24-year CEO + 4% stake + simultaneous Representative Director role at multiple MEC subsidiaries = MEC is his career and likely his single largest financial asset. No customer/supplier/competitor cross-holding surfaced. This is a high-alignment configuration.
The outside directors’ small holdings (sub-0.02% each) is normal Japanese governance practice — outside directors are paid in cash + token SBC, and their independence comes from non-equity sources. Not a red flag.
MEC’s corporate structure (per the March 2025 briefing):
MEC COMPANY LTD. (4971.T, parent)
├── MEC Japan operations (Amagasaki HQ + Nagaoka factory + Tokyo office + Kitakyushu factory under construction)
├── MEC Taiwan (est. 1990)
├── MEC Hong Kong (est. 2002)
├── MEC Suzhou — MEC China Specialty Products (est. 2001)
├── MEC Zhuhai — MEC Fine Chemical (est. 2002)
├── MEC Thailand (est. 2017)
└── MEC Europe (Belgium, est. 1992)All wholly-owned operating subsidiaries. No JVs, no minority-stake affiliates, no holding-company complexity. This is one of the cleaner corporate webs in Japanese mid-cap chemicals.
Linear. Operating subsidiaries match geographic markets. No “holdings” or “asset-management” entity wedged in the middle. No undercapitalized entities holding key assets.
Verdict: Green on shell/cross-holdings. The corporate structure is simple, the operating subsidiaries match the business model, and there are no related-party signals in public disclosure. Caveat: Yuho 関連当事者取引 needs primary-source review to fully confirm.
Specific NEO compensation amounts are not disclosed in English IR at the individual level. Japanese listed companies disclose individual NEO comp in the Yuho if any individual NEO is paid >¥100M (~$670K). For MEC at ¥204B market cap, it’s plausible the CEO clears that threshold — but I cannot confirm from English sources. Flagged as a follow-up.
Not disclosed in English. Japanese mid-cap norms are usually 1-3x base salary at CEO level; no excessive golden parachutes have been a flagged controversy. Flagged for Yuho cross-check.
None disclosed. No corporate jet usage flagged. No family members on the board (different “Maeda” — Katsuhiro Maeda — was named an outside auditor in 2012; he’s a Sumitomo Bank veteran with no apparent family relation to Kazuo Maeda confirmable from public English sources, but the surname coincidence is worth flagging for the Yuho confirmation pass).
This section cannot be fully completed for a Japanese small-cap from English-language sources alone. What I can extract:
Reconciliation with LT model (qualitative): The 2030 Vision Phase 2 plan (FY25-FY27) sets FY2027 targets of ¥25B sales and ≥20% OPM, ROE ≥10%. SBC hurdles likely sit on those numbers — meaning if management hits the plan, they get paid. FY25 actuals are already running ahead of the plan trajectory (27.1% OPM vs ≥20% target). If hurdles were set to the plan baseline, they’re easy to clear at current run-rate.
This is the single most actionable Yuho follow-up for the deep-dive — if MEC’s SBC hurdles are operational and aligned to the MTP (good), or if they’re price-only (potentially gameable), the alignment grade shifts.
Provisional grade: Yellow-Green — structure looks sensible but hurdle detail not verifiable in English.
This is a multi-year pattern of small, paced repurchases — not opportunistic timing. The Nov 2015 ¥500K share buyback was at a depressed stock price (post-China-shock); the 2023 buyback similarly was at low valuation. The 2025 buyback was executed at ~¥3,000-5,000 — much lower than the current ¥11,190. Timing has been disciplined.
Zero material equity issuance. Share count flat-to-declining. This is one of the cleanest dilution profiles in Japanese mid-cap chemicals.
The buyback discipline is good, capex is paced to qualified demand, no M&A risk, no equity dilution, and the dividend policy was explicitly upgraded during the current MTP to bind capital return to book value. Capital return scaled with profitability rather than promised at static levels.
Plotting MEC’s capital actions against TECC (= 1/forward P/E):
| Year | Avg P/E (FWD) | TECC | Buyback volume | Equity issuance | M&A | Action grade |
|---|---|---|---|---|---|---|
| 2015 | ~14x | 7.1% | 500K (large) | 0 | 0 | Good (cheap buyback) |
| 2016-18 | ~15-18x | 5.5-6.7% | 540K total | 0 | 0 | Good (steady, mod-cheap) |
| 2023 | ~10x | 10.0% | 286K | 0 | 0 | Good (very cheap buyback) |
| 2024 | ~12x | 8.3% | 0 (treasury cancelled) | 0 | 0 | Neutral |
| 2025 (Maybuyback) | ~12x est at announcement | 8.3% | 837K (incl cancellation) | 0 | 0 | Good (cheap at announce) |
| 2026 YTD | ~40x | 2.5% | 0 announced | 0 | 0 | Disciplined (no buyback at high price) |
Verdict: Capital Allocation Timing — Good. Management understands cost of equity in the way Tom Russo / Mauboussin would mean it: buyback heavy when the stock is cheap, hands-off when it’s expensive. No equity issuance ever, no banker-WACC-justified M&A. This is rare in Japanese mid-cap chemicals.
Comparing initial guide to actual / revised:
| FY | Initial OP guide | Revised guide | Actual | Variance |
|---|---|---|---|---|
| FY23 | ~¥3.0B (assumed) | n/a | ¥2.49B | Miss (cyclical 2023 PCB downturn) |
| FY24 | n/a | n/a | ¥4.56B (vs FY23 +83%) | Beat |
| FY25 | ¥5.0B (early-year) | ¥5.5B (Q3 raise) | ¥5.5B+ expected | Beat + revised up |
| FY26 | n/a yet (Q1 just printed Q1 26 May) | n/a | Q1 print ¥5.96B rev vs est ¥5.39B | Beat |
Tendency: Conservative / sandbagger in the FY25 sequence — beat early-year guide by 10% on OP and raised twice. FY26 Q1 print is a clean +11% revenue beat vs estimate. This is the highest-quality guidance pattern an investor can ask for. FY23 miss is forgivable as it was a cyclical PCB downturn that hit every name in the chain.
| Date | Source | Statement | Actual outcome | Follow-through? |
|---|---|---|---|---|
| Mar 29, 2025 | Shareholder briefing | “Kitakyushu factory scheduled to operate in 2026” | Confirmed Dec 2026 start in Feb 2026 MTP update | ✅ On track |
| Mar 29, 2025 | Briefing | “Phase 2 sales target ¥25B, OPM ≥20%, ROE ≥10% by FY2027” | FY25 9M OPM 28.3%, ROE 15.3% — running materially ahead | ✅ Exceeding |
| Mar 29, 2025 | Briefing | “Maintain market share for ultra-fine roughening adhesion” | CZ-8101 sales +20.5% YoY 9M FY25, +37.5% YoY Q3 alone | ✅ Beating |
| Mar 29, 2025 | Briefing | “30% payout ratio target” | Upgraded to 35%+ + 4%+ DoE in Dec 2025 | ✅ Upgraded (positive surprise) |
| Mar 29, 2025 | Briefing | “Flexibly implement share buybacks” | 500K cancelled Aug 2025; further commitments in Dec 2025 | ✅ Executed |
| Mar 29, 2025 | Briefing | Suzhou expansion +30% by Dec 2026 | Reconfirmed Feb 2026 MTP update | ✅ On track |
No broken promises surfaced in 12+ months of public commitments. This is a high-trust management team measured by the statement-action tape.
The Japanese English-translated IR uses standard hedge formulations (“forward-looking statements,” “actual results may differ”). I did not detect a pattern of:
The briefing material is direct and the commitments translate cleanly into action.
This is the kind of credibility that earns a small valuation premium versus peers. The flip side: a high-credibility team running ahead of guidance is exactly the kind of profile that gets aggressively re-rated — which is part of why the stock is now at 41x. Credibility is not an excuse for paying any price.
| Name | Role | Independent? | Tenure | Background |
|---|---|---|---|---|
| Kazuo Maeda | CEO, President, Representative Director | No (Internal) | 24yr Pres / 11yr CEO | Career MEC; international rollout |
| Sadamitsu Sumitomo | Director, EOO Global Ops | No (Internal) | 5.2yr | Career MEC |
| Tetsuya Taniguchi | Director, EOO | No (Internal) | 1.3yr | Career MEC |
| Mitsutoshi Takao | Outside Director, Chair of Audit & Supervisory Committee | Yes | 8.2yr | n/a English bio |
| Kaoru Hashimoto | Outside Director, AC member | Yes | 7.2yr | n/a English bio |
| Eiji Miyashita | Outside Director, AC member | Yes | 2.2yr | n/a English bio |
| Lucinda Lohman-Oota | Outside Director | Yes | 1.3yr | n/a English bio — non-Japanese, gender-diverse appointment |
7 directors total. 4 independent outside directors / 7 = 57% independent. Above the TSE Prime ⅓ threshold. Maeda is both CEO and Representative Director, but not Chairman — chairperson is a separate role per the corporate governance disclosure.
The Lohman-Oota appointment in early 2025 is a meaningful diversity signal — non-Japanese, gender-diverse, on a Japanese specialty-chemicals board. This is consistent with Maeda’s signing of the Male Leaders Coalition (per the Japanese Cabinet Office’s gender equality programme).
Explicitly excludes directors with: - Ties to 5%+ shareholders or major lenders (within 5 years). - Relationships with major trading partners or audit firms. - Close family connections to company personnel.
These criteria are stricter than the TSE Prime minimum. The fact that they’re written down and explicit is a positive governance signal.
None. No dual-class shares. No poison pill. No staggered board (Japanese companies elect the whole board annually under the Audit & Supervisory Committee structure). MEC is genuinely takeover-able if a strategic acquirer emerged — relevant given the moat and clean balance sheet.
The corporate governance disclosure explicitly states: “Board effectiveness evaluations identified ‘challenges in development and implementation of succession plans.’ The company acknowledges this remains ‘an ongoing challenge’ during the current medium-term plan period.”
This is a self-flagged governance gap. Maeda is 63 and has been President 24 years. Taniguchi was promoted to the board only 1.3 years ago and may be the seasoning successor candidate but is not publicly named as such. Sumitomo (5.2yr tenure) is also a candidate. The board has transparently acknowledged it doesn’t have this nailed.
Read: Self-acknowledged succession risk is a meaningful flag, but it’s a yellow not a red — companies that hide succession issues are worse than companies that publish them. The board’s transparency suggests an active workstream, even if not yet concluded.
| Holder type | Shares | % (ex-treasury) |
|---|---|---|
| Individuals | 5,449,991 | 27.2% |
| Financial institutions (Japanese) | 7,001,229 | 34.9% |
| Domestic corporations | 1,589,729 | 7.9% |
| Foreign corporations | 4,530,395 | 22.6% |
| Securities companies | 317,837 | 1.6% |
| Total (ex-treasury) | 18,889,181 | 100% |
Foreign ownership at 22.6% is meaningfully high for a Japanese mid-cap. Individuals at 27.2% is also high — implies a meaningful retail / family / Maeda-side block sitting in “Individuals.” This is consistent with my hypothesis that Maeda’s ~4% + family-related individuals fill out the 18.45% aggregate insider line.
From the March 2025 briefing (which fills a major prior gap):
| Region | FY24 sales (¥M) | % of total |
|---|---|---|
| Japan | 7,206 | 39.5% |
| Taiwan | 3,326 | 18.2% |
| China — Suzhou | 3,595 | 19.7% |
| China — Hong Kong + Zhuhai | 2,305 | 12.6% |
| Thailand | 810 | 4.4% |
| Europe | 989 | 5.4% |
| Total | 18,231 | 100% |
This is governance-relevant because it confirms no single overseas customer concentration risk would crater the business — even Taiwan (highest non-Japan exposure) is 18%. China total (Suzhou + Zhuhai) at 32% is the cluster to watch on geopolitical risk.
| Dimension | Rating | Key finding |
|---|---|---|
| Skin in the Game | Green | CEO 3.98% / $49M stake; aggregate insiders 18.45%; no dilutive comp practice |
| Holdings Concentration | Green | Maeda’s wealth heavily concentrated in MEC; no cross-holdings flagged |
| Shell / Cross-Holdings | Green | Clean linear corporate structure; wholly-owned operating subs; no related-party signals |
| Capital Allocation | Green (A) | Disciplined buybacks at low P/E, no equity issuance, dividend policy upgraded mid-MTP |
| Compensation Alignment | Yellow-Green | Modest SBC (~0.18%/yr); Nomination & Comp Committee majority-independent; NEO comp detail not in English |
| Credibility / Follow-Through | Green | 100% follow-through over last 12 months; conservative guidance; multiple FY25 beats |
| Governance Quality | Green | 57% independent board, no anti-takeover, strict independence criteria, board diversity move 2025 |
| Litigation / Enforcement | Green | None surfaced |
| Capital Allocation Timing | Green | Buyback at low P/E (2015, 2023, 2025), no buyback at current 41x — disciplined |
| Succession Planning | Yellow | Board self-acknowledged “ongoing challenge”; no named successor; Maeda 63 / 24yr tenure |
| Overall Management Grade | A- (Green with one Yellow flag on succession) |
I would trust this team with capital. The combination of (a) 24-year CEO with $49M of personal money in the stock, (b) disciplined buyback record across multiple cycles, (c) clean linear corporate structure, (d) 100% follow-through over the last 12 months, and (e) a governance upgrade during this MTP (dividend policy + DoE introduction + board diversity) is among the highest-quality profiles in Japanese mid-cap chemicals.
The honest yellow flag is succession. A 63-year-old CEO who has held the seat for 11 years and the presidency for 24 years, in a small company where R&D and chemistry know-how is deeply tacit, with a board that says publicly the succession plan isn’t done — that’s a real risk if Maeda steps back unexpectedly. Mitigant: he’s signed up to deliver a 2030 vision he personally articulated, and Taniguchi’s 2024 board promotion looks like seasoning.
This management quality alone doesn’t justify paying any price — the valuation work in the deep-dive concluded PASS at ¥11,190 — but at a reasonable price this is a team you can hold through cycles.
Searched ~/Dropbox/Wafflebun/KB/wiki/semianalysis/ on
2026-05-12. No direct SA coverage of MEC Company management. No SA
contradiction to flag.
None of these are deal-breakers; they’re tightening passes that would move several Yellow ratings to Green.
~/claude/output/profile/4971-profile.md,
~/claude/output/deep-dive/4971-deep-dive.md.